{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T11:54:41Z","timestamp":1686570881931},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,3,26]],"date-time":"2015-03-26T00:00:00Z","timestamp":1427328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,3,26]],"date-time":"2015-03-26T00:00:00Z","timestamp":1427328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s40264-015-0279-7","type":"journal-article","created":{"date-parts":[[2015,3,25]],"date-time":"2015-03-25T20:36:35Z","timestamp":1427315795000},"page":"365-372","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety and Effectiveness of Highly Active Antiretroviral Therapy in Treatment-Na\u00efve HIV Patients: Preliminary Findings of a Cohort Event Monitoring Study in Belarus"],"prefix":"10.1007","volume":"38","author":[{"given":"Svetlana","family":"Setkina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Dotsenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sviatlana","family":"Bondar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iryna","family":"Charnysh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alla","family":"Kuchko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alena","family":"Kaznacheeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Kozorez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alena","family":"Dodaleva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Rossa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,26]]},"reference":[{"key":"279_CR1","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1056\/NEJM199803263381301","volume":"338","author":"FJ Palella Jr","year":"1998","unstructured":"Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhre J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853\u201360.","journal-title":"N Engl J Med"},{"issue":"5","key":"279_CR2","first-page":"659","volume":"160","author":"RS Hogg","year":"1999","unstructured":"Hogg RS, Yip B, Kully C, Craib KJP, O\u2019Shaughnessy MV, Schechter MT, et al. Improved survival among HIV-infected patients after initiation of triple drug antiretroviral regimens. CMAJ. 1999;160(5):659\u201365.","journal-title":"CMAJ"},{"key":"279_CR3","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/00002030-200003310-00005","volume":"14","author":"A D\u2019Arminio Monforte","year":"2000","unstructured":"D\u2019Arminio Monforte A, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS. 2000;14:499\u2013507.","journal-title":"AIDS."},{"key":"279_CR4","first-page":"114","volume":"21","author":"S Bassetti","year":"1999","unstructured":"Bassetti S, Battegay M, Furrer H, et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 1999;21:114\u20139.","journal-title":"J Acquir Immune Defic Syndr."},{"issue":"9738","key":"279_CR5","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S0140-6736(10)60832-X","volume":"376","author":"D Wolfe","year":"2010","unstructured":"Wolfe D, Carrieri MP, Shepard D. Treatment and care for injection drug users with HIV infection: a review of barriers and ways forward. Lancet. 2010;376(9738):355\u201366.","journal-title":"Lancet."},{"key":"279_CR6","unstructured":"The world medicines situation 2011. Pharmacovigilance and safety of medicines. World Health Organization. http:\/\/apps.who.int\/medicinedocs\/documents\/s18771en\/s18771en.pdf. Accessed 18 Dec 2014."},{"key":"279_CR7","unstructured":"Monitoring Medicines Project. http:\/\/www.monitoringmedicines.org. Accessed 18 Dec 2014."},{"key":"279_CR8","unstructured":"The Uppsala Monitoring Centre. The use of WHO-UMC system for standardized case causality assessment. Available at: http:\/\/who-umc.org\/Graphics\/24734.pdf. Accessed 18 Dec 2014."},{"key":"279_CR9","unstructured":"A practical handbook on the pharmacovigilance of antiretroviral medicines. Geneva: World Health Organization; 2009. http:\/\/apps.who.int\/medicinedocs\/documents\/s16882e\/s16882e.pdf. Accessed 18 Dec 2014."},{"key":"279_CR10","unstructured":"The safety of medicines in public health programmes: pharmacovigilance an essential tool. Geneva: World Health Organization; 2006. http:\/\/www.who.int\/medicines\/areas\/quality_safety\/safety_efficacy\/Pharmacovigilance_B.pdf. Accessed 18 Dec 2014."},{"key":"279_CR11","unstructured":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. Geneva: World Health Organization; 2013."},{"key":"279_CR12","unstructured":"U.S. National Institutes of Health. Common Terminology Criteria for Adverse Events (CTCAE) v.4.0. http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm. Accessed 18 Dec 2014."},{"key":"279_CR13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharacol Ther. 1981;30:239\u201345.","journal-title":"Clin Pharacol Ther"},{"key":"279_CR14","unstructured":"Post-approval safety data management: definitions and standards for expedited reporting. E2D. ICH Harmonised Tripartite Guideline. Version 4. 12 November 2003. http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E2D\/Step4\/E2D_Guideline.pdf. Accessed 27 Feb 2015."},{"key":"279_CR15","volume-title":"Report of CIOMS Working Group III","author":"Guidelines for preparing core clinical-safety information on drugs","year":"1994","unstructured":"Guidelines for preparing core clinical-safety information on drugs. Report of CIOMS Working Group III. Geneva: CIOMS; 1994."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-015-0279-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-015-0279-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-015-0279-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-015-0279-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T17:03:16Z","timestamp":1659114196000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-015-0279-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,26]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["279"],"URL":"https:\/\/doi.org\/10.1007\/s40264-015-0279-7","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,26]]},"assertion":[{"value":"26 March 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}